CELC240517C20000
- 0.10
- 0.000.00%
Celcuity Newsroom
Celcuity Is Maintained at Buy by Stifel
Celcuity Is Maintained at Buy by Stifel
Stifel Maintains Buy on Celcuity, Maintains $40 Price Target
Stifel analyst Bradley Canino maintains Celcuity (NASDAQ:CELC) with a Buy and maintains $40 price target.
Celcuity Coverage Assumed by Craig-Hallum at Buy
Celcuity Coverage Assumed by Craig-Hallum at Buy
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Celcuity (CELC) and 89bio (ETNB)
Express News | Celcuity Inc. : Craig-Hallum Raises Target Price to $27 From $25
Express News | Needham Reiterates Buy on Celcuity, Maintains $24 Price Target
Celcuity Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 33.33% Needham → $24 Reiterates Buy → Buy 04/12/2024 33.33% Needham → $24 Reiterates Buy → Buy
Celcuity's Clinical and Financial Momentum Justifies Buy Rating and $24 Price Target
Growth Potential Drives Buy Rating for Celcuity Despite Current Losses
Celcuity (CELC) Surges After-Hours On Positive Financial Performance
After the closure of the market yesterday, Celcuity Inc. (NASDAQ: CELC) witnessed a significant uptick in its shares during the extended trading session. As per the latest update, CELC stock experienced a 4.70% increase, reaching $18.04 on the US stock market charts, following a 2.01% rise in the regular session, closing at $17.23. Strategic Milestones ...
Earnings Call Summary | Celcuity(CELC.US) Q1 2024 Earnings Conference
The following is a summary of the Celcuity Inc. (CELC) Q1 2024 Earnings Call Transcript:Financial Performance:Celcuity reported a Q1 2024 net loss of $21.6 million, an increase from its Q1 2023 net lo
Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), Celcuity (CELC) and ATAI Life Sciences (ATAI)
Celcuity Inc. (CELC) Q1 2024 Earnings Call Transcript
Celcuity Inc. (CELC) Q1 2024 Earnings Call Transcript
Celcuity Q1 Net Loss Widens; Shares Rise After Hours
Celcuity (CELC) reported a Q1 GAAP net loss late Wednesday of $0.64 per diluted share, compared with a loss of $0.55 a year earlier. Analysts polled by Capital IQ expected a loss of $0.70. No revenue
Celcuity | 10-Q: Quarterly report
Celcuity 1Q Loss/Shr 64c >CELC
Celcuity 1Q Loss/Shr 64c >CELC
Express News | Celcuity Inc: Qtrly Adj Shr Loss $0.59
Express News | Celcuity Inc: Phase 3 Viktoria-1 Trial Remains on Track to Report Topline Data From Pik3CA Wild Type Patient Sub-Group in Second Half of 2024
Express News | Celcuity Inc: $177.7 Mln in Cash, Cash Equivalents and Short-Term Investments Expected to Provide Runway Into First Half of 2026
Express News | Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update